CN107281461A - A kind of lisinopril sustained release tablets and preparation method thereof - Google Patents
A kind of lisinopril sustained release tablets and preparation method thereof Download PDFInfo
- Publication number
- CN107281461A CN107281461A CN201710440776.9A CN201710440776A CN107281461A CN 107281461 A CN107281461 A CN 107281461A CN 201710440776 A CN201710440776 A CN 201710440776A CN 107281461 A CN107281461 A CN 107281461A
- Authority
- CN
- China
- Prior art keywords
- lisinopril
- sustained release
- release tablets
- label
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Abstract
The present invention relates to sustained release tablets and its preparing technical field, more particularly to a kind of lisinopril sustained release tablets and preparation method thereof, the lisinopril sustained release tablets, it is made up of the label containing lisinopril and the coatings being wrapped in outside label, the coatings are made up of water-insoluble coating material, characterized in that, the label includes the material of following parts by weight：Sustained release tablets in 5.0%~10 part of lisinopril, 40~70 parts of porous carbon materials, the present invention have the effect of sustained release peace release, and this method technique is simple, and raw material sources are extensive, beneficial to industrialized production.
Description
Technical field
The present invention relates to sustained release tablets and its preparing technical field, more particularly to a kind of lisinopril sustained release tablets and its preparation side
Method.
Background technology
Lisinopril is the lysine derivative of enalaprilat, and belonging to has the suppression of third generation Angiotensin-Converting
Agent, lisinopril can suppress the activity of Angiotensin-Converting, make the concentration of angiotensinⅡ and aldosterone and reduce, rise
Plasma renin activity, causes peripheral vascular expansion and vascular resistence to decline, so as to produce pressure reduction effect, is primarily adapted for use in treatment former
Essential hypertension.
However, the rhythm and pace of moving things was presented in 24 hours in the characteristics of breaking-out of high blood pressure disease has circadian rhythm, the blood pressure of human body
Change, is rapidly increased to peak value, midnight to morning is down to valley, and morning peak phenomenon is two weights of blood pressure after waking up in the morning in a few hours
Want one of feature.Recognize the rhythm and pace of moving things changing rule of human blood-pressure, there is important guidance to the treatment for clinically carrying out hypertension
Meaning.Therefore, preferable antihypertensive drugs, in addition to preferable compliance, should be able to steadily be depressured in 24 hours, significantly reduce
Hyperpietic's Morning Blood Pressure, makes its degree of safety cross the high incidence period of cardiocerebrovasculaevents events, effectively protects the target devices such as the heart, brain and kidney
Official's function.For the blood pressure rhythm change of human body, select suitable medicine and in reasonable administration time, medicine is acted on and disease
The pathogenetic rhythm and pace of moving things is consistent, so as to reach the purpose of optimal therapeutic effect and reduction adverse drug reaction.
Current lisinopril preparation is conventional tablet and capsule, and it depends on blood concentration, but blood to controlling of blood pressure
Concentration has after crest and trough phenomenon, medication that blood pressure can effectively decline in a few hours, but often causes hypopiesia phenomenon,
And after drug effect, patients' blood has rebounded, often again beyond normal arterial pressure, therefore directly result in hyperpietic's blood pressure can not
Obtain more smoothly controlling, it is impossible to reach the purpose of administration, and some types processed according to the rhythm and pace of moving things of human blood-pressure well
Composition is complicated, although with certain comprehensive therapeutic effect, but unfavorable industrialized production.In order to solve the above technical problems, the patent No.
A kind of lisinopril sustained release tablets and preparation method thereof are disclosed for 201210585996.8, the present invention utilizes the pore in coatings
Agent gradually dissolve and formed drug release duct after, the medicine in label by these ducts to reach the effect of release, so as to realize
Sustained release peace sustained release puts the effect of medicine；Its rate of release is together decided on by label characteristic and coatings characteristic, due to
Technique is more complicated, and process conditions, technical parameter are difficult to control, poor reproducibility, causes rate of release also unstable.
The content of the invention
In view of the shortcomings of the prior art, the main object of the present invention is to provide a kind of lisinopril sustained release tablets and its preparation side
Method, can realize that sustained release peace sustained release puts the technique effect of medicine.
To solve the above problems, the present invention provides a kind of lisinopril sustained release tablets, by label and bag containing lisinopril
The coatings composition outside label is rolled in, the coatings are made up of water-insoluble coating material, and the label includes following weight
The material of part：5.0~10 parts of lisinopril, 40~70 parts of porous carbon materials.
The lisinopril sustained release tablets of the present invention in the label containing lisinopril by adding porous carbon materials, by Lai Nuopu
Profit absorption, with reference to the label outer cladding coatings containing lisinopril of the present invention, is released in porous carbon materials so as to produce delay
The effect put.The effect of gentle release medicine is realized under coatings and the collective effect of porous carbon materials simultaneously.
It is preferred that, the porous carbon materials are the carbonized product of non-toxic herb at high temperature, wherein the non-toxic herb is
People will not produce any adverse reaction after the plant is eaten, such as dizzy, nausea, diarrhoea phenomenon.
It is preferred that, the non-toxic herb is in algae, bryophyte, pteridophyte, gymnosperm and angiosperm
At least one；Wherein described algae can for well known to one of ordinary skill in the art, such as Nostoc commune, deliver vegetables, nostoc,
At least one of sea-tangle, pelvetia silquosa, undaria pinnitafida, seaweed, agar etc.；
The bryophyte can for well known to one of ordinary skill in the art, such as Herba Funariae Hygrometricae, marchantia, light calyx tongue, piece leaf tongue,
At least one of Ta Yetai, pin tongue, bog moss, black moss etc..
The pteridophyte can for well known to one of ordinary skill in the art, such as tuber fern, venushair fern, brake fern, Platycerium bifurcatum,
Spinulose tree fern, fan fern, new pteris fern, Selaginella tamariscina, Uncinata Spikemoss Herb, osmund, Boston fern, rabbit pin fern, button fern, petrochemical industry HERBA ONYCHII, reaping hook fern, rib
At least one of bone fern, fish tail fern, beautiful Sha fern, palm fern, steep cliff fern, holly fern etc..
The gymnosperm can be well known to one of ordinary skill in the art, larch, fir, Huashan pine, dragon spruce, Soviet Union
Iron, ephedra sinica, sweetberry jointfir, blue, silver-colored China fir at the age of one hundred years old, metasequoia, masson pine, Chinese pine, deodar, fir, ginkgo, Chinese yew, pseudotaxus chienii, fringe
At least one of Hua Shan, podocarpus, podocarpus nagi, cepehalotaxus fortunei, Chinese torreya etc..
The angiosperm can be well known to one of ordinary skill in the art, lily, diversiform-leaved poplar, Chinese ash, Chinese white poplar, mountain
Poplar, plus poplar, Lombardy poplar, dry land willow, weeping willow, white birch, elm, Chinese elm, mulberry tree, fig, yulan, wide yulan, Flos micheliae Albae, with a smile,
Liriodendron, nandina, tree peony, camellia, plane tree, hawthorn, Chinese photinia, loquat, apple, peach, Lee, apricot, hall crabapple flower, Xi Fuhai
Chinese bush cherry, chaenomeles lagenaria, pears, rose, Chinese rose, rose, cherry, oriental cherry, the late cherry of Japan, silk tree, cercis, locust tree, citrus, tree-of-heaven, perfume (or spice)
It is Chinese toon, chinaberry, smoke tree, Acer palmatum, Chinese ilex, Euonymus japonicus, Chinese littleleaf box, Buxus bodinieri, jujube, grape, the rose of Sharon, crape myrtle, pomegranate, red auspicious
Wood, dove tree, cuckoo, honeysuckle, persimmon, the capsule of weeping forsythia, winter jasmine, cloves, glossy privet, jasmine, sweet osmanthus, oleander, cape jasmine, paulownia, reach the clouds,
At least one of moundlily, mao bamboon, black bamboo, palm, coconut etc..
According to the present invention, in order to extend the slow release effect of sustained release tablets, the coating material that coatings of the invention are selected is insoluble
Yu Shui, and the pore-foaming agent in coatings dissolves after contact body fluid, makes that drug release duct can be formed after tablet for administration, in label
Medicine can only reach the effect of release by these ducts, so that realize that sustained release peace sustained release puts the effect of medicine, it is excellent
Choosing, described coating material is ethyl cellulose.It is good with heat endurance, ethanol, acetone equal solvent are soluble in, is easy to prepare
There is good compatibility between Coating Solution, and ethyl cellulose and the plasticizer selected of the present invention, at the same with label
There is good synergy between framework material.
It is preferred that, described pore-foaming agent is selected from polyethylene glycol or polyvinylpyrrolidone.With dissolubility it is good the characteristics of, make
It can rapidly be dissolved after contact body fluid, the drug release duct of insertion formed in coatings.It is described as further preferred
Pore-foaming agent is selected from polyethylene glycol.Polyethylene glycol not only has preferable dissolubility, while also having plasticization, it is possible to increase bag
The plasticity of clothing layer, makes to be not likely to produce crackle.
Also include plasticizer in described coatings, described plasticizer can improve the modeling of the coatings of the present invention
Property, make to be not likely to produce crackle.One or both of glycerine, castor oil are selected from as further preferred, described plasticizer.
Preferably, one or more of the described lubricant in magnesium stearate, talcum powder, superfine silica gel powder.Can
Play lubrication and help stream to act on.Magnesium stearate and superfine silica gel powder are selected from as further preferred, described lubricant.
Preferably, described filler is in microcrystalline cellulose, lactose, starch, pre-paying starch, sucrose, dextrin
One or more.It is one or more of in lactose, starch, microcrystalline cellulose as further preferred, described filler.
As most preferably, described filler is lactose.Lactose is water-soluble, and the obtained label containing lisinopril can be made to have light
Sliding effect attractive in appearance, and have the bioavilability for utilizing and improving lisinopril.
Preferably, the label containing lisinopril also includes adhesive.Described adhesive is normal from this area
The adhesive of rule can play a part of bonding, such as ethanol solution, polyvinylpyrrolidone, starch, ethyl cellulose,
Corresponding alcoholic solution or slurries are configured to when using, such as the ethanol solution, starch slurry, ethyl cellulose of polyvinylpyrrolidone
Ethanol solution etc..On the other hand, in order to improve the tablet quality containing lisinopril of the present invention, make to be easy to tabletting, as entering one
What is walked is preferred, and described adhesive is polyvinylpyrrolidone.
It is preferred that, in order to improve the inoxidizability of the lisinopril sustained release tablets, extend its storage time, it is preferred that institute
State and also contain antioxidant and/or preservative in the traditional Chinese medicine health care product of beautifying face and moistering lotion, it is further preferred that the antioxidant is
In butylated hydroxy anisole, dibutyl hydroxy toluene, propylgallate, tert-butylhydroquinone, tocopherol and ascorbic acid
At least one.
The preservative is benzoic acid and salt, potassium sorbate, dehydroactic acid sodium, propylparaben, calcium propionate, double
In sodium acetate, sodium lactate, streptococcus lactis, natamycin, hydrogen peroxide, sulfur dioxide, sulphite and nitrite etc.
It is at least one.
A kind of preparation method of lisinopril sustained release tablets, comprises the following steps：
(1) by non-toxic herb saline sook 10~60 minutes, after drying, it is carbonized in inert gas, obtains porous carbon
Material；
(2) by lisinopril, porous carbon materials and other auxiliary materials it is well mixed after, granulation, dry, tabletting, be made containing
The label of lisinopril；
(3) water-insoluble coating material is added in solvent and dissolved, corresponding coating solution is made, coating solution is sprayed onto and contained
Have and be coated on the label of lisinopril, coating solution is wrapped in outside the label containing lisinopril and form coatings, relied
Promise Puli's sustained release tablets.
It is preferred that, in step (1), the concentration of the salt solution is 2~35g/mL, preferably 5~15g/mL.
It is preferred that, in step (1), the temperature of the carbonization is 200~900 DEG C.
It is preferred that, in step (1), the time of the carbonization is 1~10 hour.
It is preferred that, the solvent described in step (3) is selected from least one of ethanol, acetone and water.
Compared with prior art, the present invention has following technique effect：
(1) lisinopril sustained release tablets of the invention can preferable Drug controlled release speed, upon administration the starting stage wrap
Pore-foaming agent in clothing layer gradually dissolves and forms drug release duct, the medicine of piece wicking surface is discharged by duct, forms one
The relatively low delivery platforms of individual concentration (be usually no more than content 10%)；On the other hand, moisture is entered and led to by the duct that releases the drug
Coatings are crossed, the porous carbon materials in label is absorbed water and is slowly swelled generation gel barrier to hinder internal drug to discharge, when
Porous carbon materials complete swelling simultaneously starts after slowly corrosion, and label internal drug starts at the uniform velocity to discharge with certain speed, so as to produce
Raw 2~5h drug release is sluggish (time index of its slowbreak is used as using release amount of medicine ﹤ 10%), reaches the effect of sustained release.
The tablet of the present invention is being taken at bed time with administration, morning next day start can sustained release drugs and control release amount, make blood medicine
Concentration maintains plateau all the time, improves bioavilability.
(2) lisinopril sustained release tablets of the invention have the effect that slowbreak peace sustained release is put, and are conducive to controlling the blood of patient
Pressure, but also cardiovascular and cerebrovascular morbidity risk rate can be reduced.
(3) preparation method of lisinopril sustained release tablets of the invention, extensively, cost is low for raw material sources, is adapted to industry metaplasia
Production.
Embodiment
In order to make the purpose , technical scheme and advantage of the present invention be clearer, with reference to embodiments, to the present invention
It is further elaborated.It should be appreciated that the specific embodiments described herein are merely illustrative of the present invention, it is not used to
Limit the present invention.
Embodiment 1
The invention provides a kind of lisinopril sustained release tablets, by the label containing lisinopril and the bag being wrapped in outside label
Clothing layer composition, the coatings are made up of ethyl cellulose, and the label includes the material of following parts by weight：Lisinopril 5.0
Part, 40 parts of porous carbon materials.
The preparation method of described lisinopril sustained release tablets, comprises the following steps：
(1) by Nostoc commune saline sook 10 minutes, after drying, it is carbonized in inert gas, obtains porous carbon materials, institute
The concentration for the salt solution stated is 5g/mL, and the carburizing temperature is 900 DEG C, and the time of carbonization is 1 hour；
(2) after lisinopril, porous carbon materials, polyethylene glycol, magnesium stearate, microcrystalline cellulose being well mixed, granulation,
Dry, the label containing lisinopril is made in tabletting；
(3) ethyl cellulose is added in ethanol and dissolved, corresponding coating solution is made, coating solution is sprayed onto containing depending on promise
It is coated on the label of Puli, coating solution is wrapped in outside the label containing lisinopril and form coatings, obtain lisinopril
Sustained release tablets.
Embodiment 2
The invention provides a kind of lisinopril sustained release tablets, by the label containing lisinopril and the bag being wrapped in outside label
Clothing layer composition, the coatings are made up of ethyl cellulose, and the label includes the material of following parts by weight：Lisinopril 10
Part, 70 parts of porous carbon materials.
The preparation method of described lisinopril sustained release tablets, comprises the following steps：
(1) by bog moss saline sook 60 minutes, after drying, it is carbonized in inert gas, obtains porous carbon materials, institute
The concentration for the salt solution stated is 15g/mL, and the carburizing temperature is 200 DEG C, and the time of carbonization is 10 hours；
(2) by lisinopril, porous carbon materials and polyethylene glycol, glycerine, talcum powder, sucrose, dextrin, polyvinylpyrrolidine
After ketone, propylgallate, sodium Diacetate are well mixed, pelletize, dry, the label containing lisinopril is made in tabletting；
(3) ethyl cellulose is added to the water dissolving, corresponding coating solution is made, coating solution is sprayed onto containing depending on Nuo Pu
It is coated on the label of profit, coating solution is wrapped in outside the label containing lisinopril and form coatings, is obtained lisinopril and delay
Release piece.
Embodiment 3
The invention provides a kind of lisinopril sustained release tablets, by the label containing lisinopril and the bag being wrapped in outside label
Clothing layer composition, the coatings are made up of ethyl cellulose, and the label includes the material of following parts by weight：6 parts of lisinopril,
50 parts of porous carbon materials.
Following material is also included in described lisinopril sustained release tablets：
The preparation method of described lisinopril sustained release tablets, comprises the following steps：
(1) by beautiful Sha fern saline sook 40 minutes, after drying, it is carbonized in inert gas, obtains porous carbon materials, institute
The concentration for the salt solution stated is 2g/mL, and the carburizing temperature is 400 DEG C, and the time of carbonization is 5 hours；
(2) by lisinopril, porous carbon materials and polyvinylpyrrolidone, castor oil, magnesium stearate, talcum powder, pre-pay
After change starch, starch, dibutyl hydroxy toluene, calcium propionate are well mixed, pelletize, dry, tabletting is made containing lisinopril
Label；
(3) ethyl cellulose is added in ethanol and dissolved, corresponding coating solution is made, coating solution is sprayed onto containing depending on promise
It is coated on the label of Puli, coating solution is wrapped in outside the label containing lisinopril and form coatings, obtain lisinopril
Sustained release tablets.
Embodiment 4
The invention provides a kind of lisinopril sustained release tablets, by the label containing lisinopril and the bag being wrapped in outside label
Clothing layer composition, the coatings are made up of ethyl cellulose, and the label includes the material of following parts by weight：6 parts of lisinopril,
60 parts of porous carbon materials.
The preparation method of described lisinopril sustained release tablets, comprises the following steps：
(1) by sweetberry jointfir saline sook 30 minutes, after drying, it is carbonized in inert gas, obtains porous carbon materials, institute
The concentration for the salt solution stated is 35g/mL, and the carburizing temperature is 400 DEG C, and the time of carbonization is 5 hours；
(2) by lisinopril, porous carbon materials and polyvinylpyrrolidone, castor oil, glycerine, superfine silica gel powder, lactose, second
After base cellulose, butylated hydroxy anisole, streptococcus lactis are well mixed, pelletize, dry, tabletting is made containing lisinopril
Label；
(3) ethyl cellulose is added in acetone and dissolved, corresponding coating solution is made, coating solution is sprayed onto containing depending on promise
It is coated on the label of Puli, coating solution is wrapped in outside the label containing lisinopril and form coatings, obtain lisinopril
Sustained release tablets.
Embodiment 5
The invention provides a kind of lisinopril sustained release tablets, by the label containing lisinopril and the bag being wrapped in outside label
Clothing layer composition, the coatings are made up of ethyl cellulose, and the label includes the material of following parts by weight：8 parts of lisinopril,
55 parts of porous carbon materials.
Following material is also included in described lisinopril sustained release tablets：
The preparation method of described lisinopril sustained release tablets, comprises the following steps：
(1) by plane tree saline sook 50 minutes, after drying, it is carbonized in inert gas, obtains porous carbon materials, institute
The concentration for the salt solution stated is 20g/mL, and the carburizing temperature is 400 DEG C, and the time of carbonization is 4 hours；
(2) by lisinopril, porous carbon materials and polyethylene glycol, castor oil, superfine silica gel powder, microcrystalline cellulose, tocopherol,
After sodium sulfite is well mixed, pelletize, dry, the label containing lisinopril is made in tabletting；
(3) ethyl cellulose is added to the water dissolving, corresponding coating solution is made, coating solution is sprayed onto containing depending on Nuo Pu
It is coated on the label of profit, coating solution is wrapped in outside the label containing lisinopril and form coatings, is obtained lisinopril and delay
Release piece.
Foregoing description is only the description to section Example of the present invention, not to any restriction of the scope of the invention, one's own profession
The those of ordinary skill of industry can make improvement according to the present invention or change to above-described embodiment, but belong to present invention protection model
Enclose.
Claims (9)
1. a kind of lisinopril sustained release tablets, are made up of the label containing lisinopril and the coatings being wrapped in outside label, described
Coatings are made up of water-insoluble coating material, it is characterised in that the label includes the material of following parts by weight：Lisinopril
5.0~10 parts, 40~70 parts of porous carbon materials.
2. lisinopril sustained release tablets according to claim 1, it is characterised in that the porous carbon materials are that non-toxic herb exists
Carbonized product under high temperature；
It is preferred that, the non-toxic herb be algae, bryophyte, pteridophyte, gymnosperm and angiosperm in extremely
Few one kind.
3. lisinopril sustained release tablets according to claim 1, it is characterised in that the water-insoluble coating material is ethyl
Cellulose.
4. lisinopril sustained release tablets according to claim 1, it is characterised in that also included in the lisinopril sustained release tablets
Following material：Filler, lubricant, adhesive, disintegrant, preservative, antioxidant, mouth feel modifying agents, pore-foaming agent and plasticising
At least one of agent.
5. the preparation method of the lisinopril sustained release tablets according to Claims 1 to 4 any one, it is characterised in that including
Following steps：
(1) by non-toxic herb saline sook 10~60 minutes, after drying, it is carbonized in inert gas, obtains porous carbon materials；
(2) by lisinopril, porous carbon materials and other auxiliary materials it is well mixed after, granulation, dry, tabletting, be made containing depending on promise
The label of Puli；
(3) water-insoluble coating material is added in solvent and dissolved, corresponding coating solution is made, coating solution is sprayed onto containing depending on
It is coated on the label of promise Puli, coating solution is wrapped in outside the label containing lisinopril and form coatings, obtain Lai Nuopu
Sharp sustained release tablets.
6. the preparation method of lisinopril sustained release tablets according to claim 5, it is characterised in that described in step (1)
The concentration of salt solution is 2~35g/mL, preferably 5~15g/mL.
7. the preparation method of lisinopril sustained release tablets according to claim 5, it is characterised in that described in step (1)
The temperature of carbonization is 200~900 DEG C.
8. the preparation method of lisinopril sustained release tablets according to claim 5, it is characterised in that described in step (1)
The time of carbonization is 1~10 hour.
9. the preparation method of lisinopril sustained release tablets according to claim 5, it is characterised in that described in step (3)
Solvent is selected from least one of ethanol, acetone and water.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710440776.9A CN107281461A (en) | 2017-06-13 | 2017-06-13 | A kind of lisinopril sustained release tablets and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710440776.9A CN107281461A (en) | 2017-06-13 | 2017-06-13 | A kind of lisinopril sustained release tablets and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107281461A true CN107281461A (en) | 2017-10-24 |
Family
ID=60097837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710440776.9A Pending CN107281461A (en) | 2017-06-13 | 2017-06-13 | A kind of lisinopril sustained release tablets and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107281461A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108969502A (en) * | 2018-10-11 | 2018-12-11 | 田国荣 | A kind of atenolol sustained-release piece and preparation method thereof |
| CN114699504A (en) * | 2022-06-06 | 2022-07-05 | 中孚药业股份有限公司 | Preparation method of lisinopril sustained-release tablet |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10131057A (en) * | 1996-10-21 | 1998-05-19 | Tsuu Uin:Kk | Fiber product and its production |
| CN102164615A (en) * | 2008-08-14 | 2011-08-24 | 索尼公司 | Drug sustained release agent, adsorbent, functional food, mask, and adsorptive sheet |
| CN103006612A (en) * | 2012-12-28 | 2013-04-03 | 台州职业技术学院 | Lisinopril controlled-release tablet and preparation method thereof |
| CN106365141A (en) * | 2008-09-29 | 2017-02-01 | 索尼公司 | Porous carbon material composites and their production process, adsorbents, cosmetics, purification agents, and composite photocatalyst materials |
-
2017
- 2017-06-13 CN CN201710440776.9A patent/CN107281461A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10131057A (en) * | 1996-10-21 | 1998-05-19 | Tsuu Uin:Kk | Fiber product and its production |
| CN102164615A (en) * | 2008-08-14 | 2011-08-24 | 索尼公司 | Drug sustained release agent, adsorbent, functional food, mask, and adsorptive sheet |
| CN106365141A (en) * | 2008-09-29 | 2017-02-01 | 索尼公司 | Porous carbon material composites and their production process, adsorbents, cosmetics, purification agents, and composite photocatalyst materials |
| CN103006612A (en) * | 2012-12-28 | 2013-04-03 | 台州职业技术学院 | Lisinopril controlled-release tablet and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| WENTIAN MA等: ""Fabrication of porous carbon microspheres with numerous spherical microstructure directly from waste Camellia oleifera shells and their application in sustained –release of 5-flurouracil"", 《MICROPOROUS AND MESOPOROUS MATERIALS》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108969502A (en) * | 2018-10-11 | 2018-12-11 | 田国荣 | A kind of atenolol sustained-release piece and preparation method thereof |
| CN114699504A (en) * | 2022-06-06 | 2022-07-05 | 中孚药业股份有限公司 | Preparation method of lisinopril sustained-release tablet |
| CN114699504B (en) * | 2022-06-06 | 2022-08-09 | 中孚药业股份有限公司 | Preparation method of lisinopril sustained-release tablet |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100814253B1 (en) | Phase transitive breath care products | |
| MXPA02006473A (en) | Odormasking coating for a pharmaceutical preparation. | |
| CN107281461A (en) | A kind of lisinopril sustained release tablets and preparation method thereof | |
| CN106420482A (en) | Skin energy activating sparkling essence | |
| CN103006612B (en) | Lisinopril controlled-release tablet and preparation method thereof | |
| CN108338976A (en) | A kind of nifedipine double-layer osmotic pump tablet and preparation method thereof | |
| KR101272738B1 (en) | Method for the preparation of oral capsule and the oral composition containing the capsule powder prepared by the same | |
| CN103550183A (en) | Trimetazidine hydrochloride osmotic pump controlled-release tablet and preparation method thereof | |
| CN111109650B (en) | Water-based liquid pill applied to cigarettes and preparation method thereof | |
| CN109758372A (en) | A kind of pellet and preparation method thereof with preparing the application in oral care product | |
| CN107029208A (en) | It is a kind of to treat lisinopril compound preparation of angiocardiopathy and preparation method thereof | |
| JP3759949B2 (en) | Shielding agent and coating composition | |
| CN107281150A (en) | A kind of simvastatin slow-release tablet of reducing blood lipid and preparation method thereof | |
| CN102552247B (en) | Composition of vitamin C and preparation method thereof | |
| CN102349880A (en) | Isradipine controlled-release tablets and preparation method thereof | |
| CN102895211A (en) | Sudden death and hypertension resistant metoprolol intelligent medicine release system and its preparation method | |
| CN106474137B (en) | A kind of film for treating oral ulcer containing chlorophyll and preparation method thereof | |
| CN107582557A (en) | A kind of pharmaceutical composition for treating cerebral apoplexy | |
| CN111821266A (en) | Taurine sustained-release composition and preparation method thereof | |
| CN1631395A (en) | Gingko leaf sustained release formulation and preparation process thereof | |
| CN102934768B (en) | Puerarin, pine pollen and propolis composite tablet and preparation method thereof | |
| CN201320299Y (en) | Nifuratel coated tablet | |
| IE840817L (en) | Novel galenic forms of sulpiride which can be used orally | |
| CN106511471B (en) | A kind of fig oral spray and preparation method thereof | |
| CN107753459A (en) | A kind of vitamin C effervescent tablet and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20171024 |